October 12, 2023

BioPharmGuyNews.png

Purchase Data

Promoted Listings

An altogether different kind of CDMO 


With global Pfizer expertise we’re dedicated to being your reliable OSD manufacturing partner, from clinical to commercial.  


What to find out more? Meet with our team at CPHI Barcelona at booth #3J50 


Schedule a meeting today

BioPharmGuy

Well, last week it finally happened. I put the wrong date at the top of the email. Had a good 192-week streak going. Ah well. Still working on a seven perfects-in-a-row NYT Connections streak, so there's that.


Crunched

A client was interested in a data set and had follow-up questions on a sample we sent. One was why our funding data wasn’t as comprehensive as Crunchbase. 


If you’re not aware, Crunchbase’s whole operation is dedicated to tracking funding. So yeah – we are going to admit BioPharmGuy is not quite as good at tracking funding as the best private funding tracker in the world. Know what else? We don't have as much info on publicly traded companies as Bloomberg.


But what we do have is market leadership on tracking biotech companies. For example, two of the largest data providers in America have purchased our information for marketing purposes rather than relying on their own data. Take from that what you will.


.ma

Of the 11,000 websites we list, how many got clever and picked a url like “xxxxbiophar.ma” utilizing Morocco’s top-level domain? 


One.


Here’s to you, Cage Pharma


Companies Added & Removed

34 companies added, 25 removed.


Best New Name:

Torque Bio


Worst New Name:

Orakl Oncology


You Will Be Missed:

Immunome


Excel summary file of adds/removals available free on our downloads page.

Industry

As You Were

Amgen's acquisition of Horizon Therapeutics closed on Friday after a long fight with the FTC. It ended with Amgen triple pinky-promising not to use the acquisition to wrench more loot from hospitals. Congratulations, consumers - you are officially protected!


No, but in reality, this was a weird stockblock by the FTC. There was no real overlap between product lines. The feds really tried to stretch logic by suggesting Amgen would somehow force buyers to take the Horizon products even though there are competitors out there.


If they could magically do such a thing, wouldn't they be charging even more for their existing products using the same tactics?


Yeast Affection

This company called Chai Bio is doing nothing tea-related, though they are closer than you might suppose. They have a couple business lines for their qPCR testing. One is for breweries testing for beer spoilage. The other is Covid-19.


What is this, early 2021?


Name N/A

DNA, RNA - we see these all the time in biotech company names and literature. But we would strongly advise against using TNA.


Unfortunately, the horse is out of the barn on that one – TNA Therapeutics is on full display.


Biotech Imbalances

A big group picture with everyone dressed casually is a cool element for a careers page. But maybe not quite as cool when you have over 50 employees and still carry a 3:1 ratio in favor of women. 


Although what's more iniquitous is probably the 3:1 ratio in favor of men amongst biotech Founders.


And it's not just founders. Here's a company proudly displaying their eight-member management team made entirely of white-clad men. Almost cult-like.


Maybe women are making a rational decision flocking to certain companies?


Corporate Agrimony

Indianapolis-based Corteva, who produces genetically modified seeds, is accusing fellow AgBio company, Inari (Cambridge, MA), of surreptitiously obtaining their seeds, slightly modifying them, then reproducing for sale. 


These are some saladious allegations. (too much?)


We don’t know anything about the particulars, but we do know Inari has been dramatically expanding their location just down the street from BioPharmGuy HQ in West Lafayette, which is a mere 68-minute drive from the Corteva spot down in Indy. The proximity is at least interesting.


Team Roast - Bounced Check

Welcome to our website. Check out our team, consisting of team members. Then head over to the Investor tab to see when the cheesesteak festival is. Please check out our products. We have four. Thank you for visiting.


Positron

This PET imaging company announced via press release that they sold off their Attrius PET system, which would be pretty much the biggest possible news for a small medical device company.


Alas, upon closer reading, what they meant was they sold a system, not the system. Slightly different level of newsworthiness. But always fun to see the "we sold something" press release. Way to go, champs!


Dog Days

Last week we talked about DNA tests for dogs. This week let’s profile some of our favorite dogs of biotech.


First, scroll down a ways here and you will eventually find yourself staring at Messi, who is the Chief Bonding Officer at ComboTope Therapeutics. Judging by his demeanor, you can depend on this Messi – no spending $500 only for him to sleep all day. Good boy!


Then we have Penelope, the Chief Morale Officer at Absci. Cute, but we really think they missed the opportunity of placing a Chief Canine Officer directly next to their Chief People Officer.


But that’s ok because Rocco at BiterrootBio holds that exact title. He even has an additional one as well: Head of Barketing.


Give those dogs some treats!

Health & Science

Chemotherapy Drug Shortage

In an ongoing saga, the US chemotherapy drug market is failing miserably. The drugs are generic and thus cheap, so there is little financial incentive for most producers. So, what the sickest patients are left with are supply droughts. Wonderful.


The situation degraded to the point where FDA allowed certain drugs to be shipped in from Chinese factories that are not approved by FDA. To put that into perspective, producers in countries like India and China who are inspected/approved by FDA still end up with laundry lists of citations at most inspections. In fact, part of the current shortage is sue to an Indian chemotherapy producer which was inspected by FDA and proved so deficient, they chose to shut down instead of correcting things.


We don't have to accept this. It's about time the US government created a public health initiative whereby they manufacture cheap medicines that have low market incentives but provide high value to Americans. We have not heard much talk about this concept, but when life-saving markets fail, that is certainly a reasonable time for government to step in.


The science and technology behind generic production is well-established, and functionally, it's relatively simple at this point. The alternative of letting children sit around waiting for chemo medicines while their cancer grows is untenable.


Old News

A Swedish study of people who made it to the age of 100 looked at blood samples from these people taken at earlier (though still old) ages and found 12 blood-based molecules that correlated with eventually making it a century. Oddly, one of the markers was an increased level of total cholesterol. Per the article:


“Higher levels of total cholesterol and iron and lower levels of glucose, creatinine, uric acid, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, and total iron-binding capacity were associated with reaching 100 years.”


This cholesterol information is interesting considering it seems to be public enemy #1 for cardiovascular health. As ever, more studies are needed. 


In a related super-old-people item, pockets of exceptionally old-aged people have seemed to thrive in parts of Japan and Italy leading some to suggest maybe drinking red wine, eating a lot of fish and vegetables, or whatever people do in those places is the secret to long life.


Well, there seems to be an easier explanation for their amazingly old age – fabrication.


The hotspots around the world for supercentenarians (those making it to age 110) just so happen to be places late to the game on formalizing birth certificates. In these places people are also poorer, live shorter lives and are located in richer countries with decent old-age welfare systems. After these regions modernized their birth certificate systems – presto, no one’s living to 110 anymore!


How odd.


Chow Down

A news piece last week implied Walmart was blaming Ozempic for making people buy less food.


First, what else would you expect an appetite-suppressant to do?


But second, Walmart did not say food sales are dropping in aggregate. They were saying based on surveys of a small group of individuals, they see Ozempic-takers are buying less food than they used to. Which is entirely the point.


But those people will need new clothes...Walmart always wins.

Promote Your Listing at BioPharmGuy

Check your website's analytics - BioPharmGuy is likely your top referrer.


Bump up those referrals even more with a Premium Listing. Learn more - Promoted Listings.

Subscribe!

If you're reading this and not a subscriber, please join our mailing list.

BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2023 Wilsonian LLC